Drugs / SCTB39G
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07665970 | Jun 2026 → Jun 2029 expected | cancer | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07077252 | Jul 2025 → Sep 2027 expected | cancer | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCTB39G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07665970 ↗ |
| Route | Intravenous | “SCTB39G,IV” NCT07077252 ↗ |